BMS’s Revlimid Loss Of Exclusivity Is Not As Bad As Expected, But Not For Long
Executive Summary
The company credited generics’ late market entry, but that benefit is not expected to last; the firm lowered guidance for annual sales of the oncologic. The firm stressed growth opportunities ahead for Opdivo, Opdualag and Camzyos.
You may also be interested in...
Zydus Looks To Revlimid Opportunity, Pivots To Multivariant COVID-19 Vaccine
Zydus is looking to launch a Revlimid generic in the second wave while an opportunity might soon emerge from Takeda’s Pentasa. It is also pivoting to a multivariant version of its plasmid DNA vaccine against COVID-19, ZyCoV-D, after the original didn’t receive an encouraging response.
Zydus Pivots To Multivariant COVID-19 Vaccine, Looks To Revlimid Opportunity
Zydus is pivoting to a multivariant version of its plasmid DNA vaccine against COVID-19, ZyCoV-D, after the original didn’t receive an encouraging response. It also looks to launch a Revlimid generic in the second wave while an opportunity might soon emerge from Takeda’s Pentasa.
Bristol’s Opdivo Stumbles On Its Way To First-Line Bladder Cancer Indication
The CheckMate-901 trial failed on one of its primary endpoints, but the company will continue the trial to explore additional primary endpoints.